%0 Practice Guideline
%T Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation.
%A Ponce DM
%A Politikos I
%A Alousi A
%A Carpenter PA
%A Milano F
%A MacMillan ML
%A Barker JN
%A Horwitz ME
%A  
%J Transplant Cell Ther
%V 27
%N 7
%D 07 2021
%M 34210500
暂无%R 10.1016/j.jtct.2021.03.012
%X The incidence of graft-versus-host disease (GVHD) after cord blood (CB) transplantation (CBT) is lower than expected given the marked degree of human leukocyte antigen (HLA)-mismatch of CB grafts. While the exact mechanism that underlies this biology remains unclear, it is hypothesized to be due to the low number of mostly immature T-cells infused as part of the graft1,2, and increased tolerance of CB-derived lymphocytes induced by the state of pregnancy. Nevertheless, acute GVHD (aGVHD) is a significant complication of CBT. In contrast, the incidence of chronic GVHD (cGVHD) following CBT is lower than what is observed following matched related or unrelated donor HSC transplantation (HSCT)3-6. This review outlines the guidelines for the prevention and management of acute and chronic GVHD following CBT.